Diabetic Agents, From Metformin to SGLT2 Inhibitors and GLP1 Receptor Agonists: JACC Focus Seminar
T Wilcox, C De Block, AZ Schwartzbard… - Journal of the American …, 2020 - jacc.org
Given the intersection between diabetes mellitus and cardiovascular disease (CVD),
pharmacologic agents used to treat type 2 diabetes mellitus must show cardiovascular …
pharmacologic agents used to treat type 2 diabetes mellitus must show cardiovascular …
Cardiorenal protection: potential of SGLT2 inhibitors and GLP-1 receptor agonists in the treatment of type 2 diabetes
T Nagahisa, Y Saisho - Diabetes Therapy, 2019 - Springer
Recent large clinical trials on sodium-glucose cotransporter 2 (SGLT2) inhibitors and
glucagon-like peptide-1 (GLP-1) receptor agonists, with the aim of verifying cardiovascular …
glucagon-like peptide-1 (GLP-1) receptor agonists, with the aim of verifying cardiovascular …
Cardiovascular outcomes of sodium-glucose cotransporter 2 inhibitors: a comprehensive review of clinical and preclinical studies
Diabetes is a leading cause of morbidity and mortality worldwide. Management of diabetes
is changing at a rapid pace. Three new classes of antidiabetic drugs including GLP-1 …
is changing at a rapid pace. Three new classes of antidiabetic drugs including GLP-1 …
[HTML][HTML] Impact of glucose-lowering medications on cardiovascular and metabolic risk in type 2 diabetes
Type 2 Diabetes Mellitus (T2DM) is associated with a high risk of atherosclerotic
cardiovascular (CV) disease. Among the well-known pathophysiologic factors, crucial roles …
cardiovascular (CV) disease. Among the well-known pathophysiologic factors, crucial roles …
Glucose-lowering drugs to reduce cardiovascular risk in type 2 diabetes
RR Kalyani - New England Journal of Medicine, 2021 - Mass Medical Soc
Key Clinical Points Glucose-Lowering Drugs to Reduce Cardiovascular Risk in Type 2
Diabetes The attainment of glycemic targets and comprehensive reduction in risk factors for …
Diabetes The attainment of glycemic targets and comprehensive reduction in risk factors for …
Glucose-lowering therapies in patients with type 2 diabetes and cardiovascular diseases
F Prattichizzo, L La Sala, L Ryden… - European journal of …, 2019 - academic.oup.com
Type 2 diabetes mellitus is a major risk factor for developing cardiovascular disease, and
many patients with diabetes have prevalent cardiovascular complications. Recent …
many patients with diabetes have prevalent cardiovascular complications. Recent …
Mechanisms by which glucagon-like-peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors reduce cardiovascular risk in adults with type 2 …
The growing global burden of type 2 diabetes mellitus confers significant morbidity and
mortality in addition to significant cost to local health-care systems. In recent years, 2 classes …
mortality in addition to significant cost to local health-care systems. In recent years, 2 classes …
Novel diabetes drugs and the cardiovascular specialist
Recently, treatment with 2 newer classes of type 2 diabetes drugs were found to reduce
events in patients with diabetes and cardiovascular (CV) disease, a group common in …
events in patients with diabetes and cardiovascular (CV) disease, a group common in …
GLP-1 receptor agonists and SGLT2 inhibitors for the treatment of type 2 diabetes: new insights and opportunities for cardiovascular protection
L Bertoccini, MG Baroni - Diabetes: from Research to Clinical Practice …, 2021 - Springer
The risk of cardiovascular disease (CVD)(myocardial infarction, stroke, peripheral vascular
disease) is twice in type 2 diabetes (T2D) patients compared to non-diabetic subjects …
disease) is twice in type 2 diabetes (T2D) patients compared to non-diabetic subjects …
Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and …
TA Zelniker, SD Wiviott, I Raz, KA Im, EL Goodrich… - Circulation, 2019 - Am Heart Assoc
Background: Glucagon-like peptide 1 receptor agonists (GLP1-RA) and sodium-glucose
cotransporter-2 inhibitors (SGLT2i) have emerged as 2 new classes of antihyperglycemic …
cotransporter-2 inhibitors (SGLT2i) have emerged as 2 new classes of antihyperglycemic …
相关搜索
- receptor agonists sglt2 inhibitors
- diabetic agents sglt2 inhibitors
- receptor agonists cardiovascular protection
- receptor agonists sodium glucose
- receptor agonists diabetes mellitus
- cardiovascular protection sglt2 inhibitors
- mechanistic insights sglt2 inhibitors
- receptor agonists cardiorenal protection
- receptor agonists cardiovascular risk
- cardiovascular disease sglt2 inhibitors
- cardiorenal protection sglt2 inhibitors